Cost Saving

PHILADELPHIA — Icosapent ethyl for patients at high CV risk conferred cost-savings in-trial and during patients’ lifetime, according to findings presented at the American Heart Association Scientific Sessions.

Patients who underwent nutrition-focused care that consisted of malnutrition risk screening and at-home use of oral nutritional supplements reduced their risk for hospitalization by almost 25%, according to findings recently published in the Journal of Parenteral and Enteral Nutrition.